about
Gene therapy on the moveAltering murine leukemia virus integration through disruption of the integrase and BET protein family interactionIntravenous injection of a foamy virus vector to correct canine SCID-X1.Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.Serial number tagging reveals a prominent sequence preference of retrotransposon integrationNewborn screening for severe combined immunodeficiency in 11 screening programs in the United States."Model t" cells: a time-tested vehicle for gene therapyRetargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes.Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.Modern management of primary T-cell immunodeficiencies.Human artificial chromosome-based gene delivery vectors for biomedicine and biotechnology.Clinical potential of gene therapy: towards meeting the demand.Moonlighting adenosine deaminase: a target protein for drug development.Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesisGenome editing: a tool for research and therapy: targeted genome editing hits the clinic.Impacts of leukocyte filtration and irradiation on coagulation factors in fresh frozen plasma.Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system.Rare Genetic Blood Disease Modeling in Zebrafish
P2860
Q27007012-D5EA02A2-1DDE-41F5-8BC2-49BA3C3959F7Q27682160-D796EA81-D4FE-4AD5-8AA7-73B77260CB6DQ30409845-439A8B16-FB0A-4453-A1A4-3B8BFBB76440Q33415221-F99759B0-14BE-443A-A27A-6A812D44CAE6Q33782832-D23A6E28-3401-4181-8D71-85988695C70DQ33983578-CAB02E11-7810-4D91-9574-DAE682427AA1Q35820252-EFC43441-7369-4D5F-A868-C036C891D8EBQ37201423-D1CBA86B-CB23-4D26-8F3A-4F4C39523315Q37393882-1224114F-E464-4879-86B0-09F2C41AE177Q37616952-38B31168-265E-4245-B10D-5C6E158409AAQ38175191-1B01D87F-9620-4F5B-9162-D9463DC2AB18Q38183464-0D78BD1D-2EBE-4F6B-AFE0-9D1C63CF364CQ38195338-07D0AD80-682E-4948-8340-D2181FB687CEQ38220597-0C6E8F68-117F-48D1-BB4D-574717200AFEQ38788187-399DFB63-9044-4BF7-BB72-C6114414B042Q39416850-761CEC3B-DCD2-4154-880B-DFD87DC7A312Q41711054-B50EB5B8-03AB-4D6F-BE01-1602B8D52CB8Q43086824-A50E7B9E-43C1-4372-905C-345E074AE527Q44807937-BB12B349-5A41-4A16-92E0-5AEB69B5FFFDQ58780870-B3EA1828-A32C-4995-A10A-22EACEB67D50
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Gene therapy of primary T cell immunodeficiencies.
@en
type
label
Gene therapy of primary T cell immunodeficiencies.
@en
prefLabel
Gene therapy of primary T cell immunodeficiencies.
@en
P50
P1433
P1476
Gene therapy of primary T cell immunodeficiencies.
@en
P304
P356
10.1016/J.GENE.2013.03.092
P407
P577
2013-04-10T00:00:00Z